Kyriazopoulou, Evdoxia
Hasin-Brumshtein, Yehudit
Midic, Uros
Poulakou, Garyfallia
Milionis, Haralampos
Metallidis, Simeon
Astriti, Myrto
Fragkou, Archontoula
Rapti, Aggeliki
Taddei, Eleonora
Kalomenidis, Ioannis
Chrysos, Georgios
Angheben, Andrea
Kainis, Ilias
Alexiou, Zoi
Castelli, Francesco
Serino, Francesco Saverio
Bakakos, Petros
Nicastri, Emanuele
Tzavara, Vasiliki
Ioannou, Sofia
Dagna, Lorenzo
Dimakou, Katerina
Tzatzagou, Glykeria
Chini, Maria
Bassetti, Matteo
Kotsis, Vasileios
Tsoukalas, Dionysios G.
Selmi, Carlo
Konstantinou, Alexandra
Samarkos, Michael
Doumas, Michael
Masgala, Aikaterini
Pagkratis, Konstantinos
Argyraki, Aikaterini
Akinosoglou, Karolina
Symbardi, Styliani
Netea, Mihai G.
Panagopoulos, Periklis
Dalekos, George N.
Liesenfeld, Oliver
Sweeney, Timothy E.
Khatri, Purvesh
Giamarellos-Bourboulis, Evangelos J.
Funding for this research was provided by:
Inflammatix
Swedish Orphan Biovitrum
Hellenic Institute for the Study of Sepsis
Article History
Received: 11 January 2024
Accepted: 27 February 2024
First Online: 12 March 2024
Declarations
:
: SAVE-MORE double-blind randomized clinical trial (NCT04680949) was conducted in accordance with the declaration of Helsinki and national and institutional standards. The protocol and informed consent form were approved by the National Ethics Committee of Greece (approval 161/20) and by the Ethics Committee of the National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, in Rome (1 February 2021). All patients or their legal representatives provided written informed consent before study enrollment.
: Not applicable.
: GND is an advisor or lecturer for Pfizer, Roche, Sanofi, Sobi, and Genesis and received research grants from Gilead and has served as PI in studies for Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics Inc., Sobi and Intercept Pharmaceuticals. MGN is a scientific founder of TTxD, Biotrip and Lemba and was supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. PK is a co-founder of, holds stock options of and a consultant to Inflammatix, Inc. YH-B, UM, OL and TES are employees and stock option holders of Inflammatix, Inc. EJGΒ has received honoraria from Abbott Products Operations, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH and Swedish Orphan BioVitrum; independent educational grants from Abbott Products Operations, bioMérieux Inc, InCyte, Johnson & Johnson, MSD, UCB and Swedish Orphan BioVitrum; and funding from the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). All other authors do not declare conflicts of interest.